 Divij Mathew
Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD8-Positive T-Lymphocytes | 13 | 2025 | 917 | 2.110 |
Why?
| | Programmed Cell Death 1 Receptor | 5 | 2025 | 264 | 1.700 |
Why?
| | Janus Kinase 1 | 1 | 2024 | 26 | 0.850 |
Why?
| | CTLA-4 Antigen | 2 | 2024 | 104 | 0.840 |
Why?
| | Janus Kinase Inhibitors | 1 | 2024 | 28 | 0.830 |
Why?
| | Receptors, Lysophosphatidic Acid | 2 | 2021 | 40 | 0.750 |
Why?
| | Immunologic Memory | 7 | 2025 | 366 | 0.740 |
Why?
| | Tumor Escape | 1 | 2021 | 49 | 0.650 |
Why?
| | Betacoronavirus | 2 | 2020 | 286 | 0.640 |
Why?
| | Lysophospholipids | 1 | 2021 | 77 | 0.640 |
Why?
| | GTP-Binding Protein alpha Subunits, G12-G13 | 1 | 2019 | 8 | 0.590 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2019 | 177 | 0.560 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 384 | 0.560 |
Why?
| | Coronavirus Infections | 2 | 2020 | 378 | 0.550 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 444 | 0.530 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 668 | 0.490 |
Why?
| | B-Lymphocytes | 2 | 2021 | 877 | 0.460 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 1182 | 0.440 |
Why?
| | T-Lymphocytes | 2 | 2020 | 1982 | 0.440 |
Why?
| | Signal Transduction | 4 | 2022 | 5233 | 0.360 |
Why?
| | Flow Cytometry | 2 | 2025 | 1173 | 0.330 |
Why?
| | Lung Neoplasms | 1 | 2024 | 2642 | 0.330 |
Why?
| | B-Lymphocyte Subsets | 2 | 2020 | 80 | 0.310 |
Why?
| | Neoplasms | 3 | 2021 | 2884 | 0.290 |
Why?
| | Immunophenotyping | 3 | 2024 | 322 | 0.270 |
Why?
| | Lymphocyte Activation | 5 | 2023 | 1126 | 0.250 |
Why?
| | Antibodies, Viral | 4 | 2023 | 672 | 0.220 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily D | 1 | 2024 | 2 | 0.220 |
Why?
| | Antigens, CD | 2 | 2024 | 555 | 0.200 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2024 | 202 | 0.190 |
Why?
| | Complement C5a | 1 | 2022 | 54 | 0.180 |
Why?
| | Receptors, IgG | 1 | 2022 | 76 | 0.180 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2022 | 35 | 0.180 |
Why?
| | Lymphocytic Choriomeningitis | 1 | 2021 | 25 | 0.170 |
Why?
| | Mice, Inbred C57BL | 6 | 2025 | 5997 | 0.170 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 30 | 0.170 |
Why?
| | Thromboembolism | 1 | 2022 | 125 | 0.170 |
Why?
| | Th1 Cells | 1 | 2021 | 139 | 0.160 |
Why?
| | Animals | 9 | 2025 | 38109 | 0.160 |
Why?
| | Antigens, Viral | 1 | 2021 | 182 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 781 | 0.160 |
Why?
| | Plasma Cells | 1 | 2020 | 79 | 0.160 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2020 | 131 | 0.150 |
Why?
| | Perforin | 1 | 2019 | 21 | 0.150 |
Why?
| | Immunotherapy | 1 | 2024 | 657 | 0.150 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2019 | 53 | 0.150 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2019 | 27 | 0.150 |
Why?
| | Adaptive Immunity | 1 | 2020 | 169 | 0.150 |
Why?
| | Hematologic Neoplasms | 1 | 2021 | 162 | 0.150 |
Why?
| | CD8 Antigens | 1 | 2019 | 72 | 0.140 |
Why?
| | Exocytosis | 1 | 2019 | 84 | 0.140 |
Why?
| | Lymphocyte Depletion | 1 | 2019 | 132 | 0.140 |
Why?
| | Blood Platelets | 1 | 2022 | 400 | 0.140 |
Why?
| | Mice | 7 | 2025 | 18365 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 2020 | 415 | 0.140 |
Why?
| | Melanoma | 1 | 2024 | 761 | 0.130 |
Why?
| | Humans | 15 | 2025 | 144957 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2019 | 229 | 0.130 |
Why?
| | Cells, Cultured | 3 | 2022 | 4155 | 0.130 |
Why?
| | Single-Cell Analysis | 3 | 2025 | 359 | 0.130 |
Why?
| | Lymphocytes | 1 | 2019 | 382 | 0.130 |
Why?
| | Cell Differentiation | 5 | 2025 | 2050 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2022 | 2925 | 0.120 |
Why?
| | Cytokines | 2 | 2020 | 2065 | 0.110 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2015 | 17 | 0.110 |
Why?
| | Multipotent Stem Cells | 1 | 2015 | 21 | 0.110 |
Why?
| | Pandemics | 2 | 2020 | 1695 | 0.110 |
Why?
| | Radiation, Ionizing | 1 | 2015 | 87 | 0.110 |
Why?
| | Mice, Knockout | 2 | 2019 | 3125 | 0.110 |
Why?
| | Neutrophils | 1 | 2020 | 1134 | 0.110 |
Why?
| | Receptors, Notch | 1 | 2015 | 92 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2020 | 1129 | 0.100 |
Why?
| | Female | 10 | 2024 | 78376 | 0.100 |
Why?
| | Calcium | 1 | 2019 | 1184 | 0.100 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2185 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2015 | 420 | 0.090 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2024 | 223 | 0.090 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2023 | 130 | 0.090 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3550 | 0.080 |
Why?
| | Immunity, Humoral | 2 | 2021 | 120 | 0.080 |
Why?
| | Antibodies, Neutralizing | 2 | 2023 | 341 | 0.080 |
Why?
| | Immunity, Cellular | 2 | 2021 | 272 | 0.080 |
Why?
| | Inflammation | 1 | 2021 | 2880 | 0.070 |
Why?
| | Time Factors | 1 | 2020 | 7183 | 0.070 |
Why?
| | Middle Aged | 5 | 2023 | 35928 | 0.070 |
Why?
| | Male | 8 | 2024 | 72406 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8279 | 0.070 |
Why?
| | Young Adult | 2 | 2021 | 14126 | 0.060 |
Why?
| | Algorithms | 2 | 2025 | 1839 | 0.060 |
Why?
| | Epigenesis, Genetic | 2 | 2021 | 685 | 0.060 |
Why?
| | Aged | 3 | 2021 | 25947 | 0.060 |
Why?
| | Adult | 4 | 2023 | 40506 | 0.060 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 1 | 2024 | 9 | 0.050 |
Why?
| | Automation | 1 | 2025 | 102 | 0.050 |
Why?
| | High Mobility Group Proteins | 1 | 2024 | 45 | 0.050 |
Why?
| | Vaccination | 2 | 2023 | 1423 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2024 | 2499 | 0.050 |
Why?
| | Syk Kinase | 1 | 2022 | 22 | 0.050 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 21 | 0.040 |
Why?
| | Lectins, C-Type | 1 | 2021 | 62 | 0.040 |
Why?
| | Vero Cells | 1 | 2021 | 84 | 0.040 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2021 | 100 | 0.040 |
Why?
| | Platelet Activation | 1 | 2022 | 104 | 0.040 |
Why?
| | Core Binding Factor Alpha 3 Subunit | 1 | 2021 | 6 | 0.040 |
Why?
| | Lymphocytic choriomeningitis virus | 1 | 2021 | 36 | 0.040 |
Why?
| | Morpholines | 1 | 2022 | 129 | 0.040 |
Why?
| | Aminopyridines | 1 | 2022 | 127 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 91 | 0.040 |
Why?
| | Cricetinae | 1 | 2021 | 304 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 469 | 0.040 |
Why?
| | Clonal Selection, Antigen-Mediated | 1 | 2020 | 5 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2020 | 164 | 0.040 |
Why?
| | CRISPR-Cas Systems | 1 | 2021 | 170 | 0.040 |
Why?
| | Adoptive Transfer | 1 | 2019 | 198 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 320 | 0.030 |
Why?
| | Pyrimidines | 1 | 2022 | 533 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1325 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2021 | 1540 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2092 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2119 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2882 | 0.030 |
Why?
| | Peptides | 1 | 2021 | 998 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1813 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1496 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1958 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2020 | 846 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2019 | 1524 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2434 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5965 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7997 | 0.020 |
Why?
|
|
Mathew's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|